Clinical Trial Update: Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating osimertinib alone or with chemotherapy in advanced non-small cell lung cancer with concurrent EGFR and TP53 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Li Zhang, MD | Conditions: Non-small Cell Carcinoma, EGFR Gene Mutation | Phase 3 | Status: ACTIVE_NOT_RECRUITING